Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 50%GRADE not reported 0 · 0%Very low 2 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

Treatment success as defined by the authors · people with Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

Pain frequency or change in pain frequency · people with Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

At least 30% reduction in pain · people with Crohn's disease

It is very uncertain whether 100 mg olorinab 3 times/day changes pain intensity (30% reduction in weekly AAPS) compared with 25 mg olorinab 3 times/day (very low certainty).

1 finding from 1 review

Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
RR 0.66 [0.38, 1.15]
1 study · 14 participants
Very low

100 mg olorinab 3 times/day vs 25 mg olorinab 3 times/day

Withdrawals due to adverse events · people with Crohn's disease

1 finding from 1 review

Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low